Since the expression of ChREBP, especially the ChREBP-β isoform, is often downregulated in conditions predisposing to diabetes, therefore, restoration of ChREBP expression or activity in WATs might be an important therapeutic strategy to treat T2D and its complications. Here, MLXIPL is linked to type 2 diabetes mellitus.